In in-vitro and in-vivo studies, Qian and colleagues82 showed that a GLP-1R agonist changed activated M1 microglia to the M2 subtype, and thus is a potential therapeutic agent for the attenuation of cognitive impairment in patients with schizophrenia. The gene discussed is GLP1R; the disease is Cognitive impairment.